Royalty Pharma plc Class A Ordinary Shares (RPRX) Dividend History

Royalty Pharma plc (RPRX) is a pharmaceutical royalty financial company that acquires royalties from commercialized medicines, biotechnological innovations, and research and development programs. Established as a leading player in the royalty monetization sector, it provides capital to biopharmaceutical companies and researchers while generating revenue from the royalties it holds on successful drug sales.

110 East 59th Street, New York, NY, 10022
Phone: (212) 883-0200
Website: https://www.royaltypharma.com

Dividend History

Pay Date	Amount	Ex Dividend Date	Record Date
June 10, 2025	$0.22	05/16/2025	05/16/2025
March 10, 2025	$0.22	02/21/2025	02/21/2025
December 10, 2024	$0.21	11/15/2024	11/15/2024
September 13, 2024	$0.21	08/16/2024	08/16/2024
June 14, 2024	$0.21	05/16/2024	05/17/2024
March 15, 2024	$0.21	02/15/2024	02/16/2024
December 15, 2023	$0.20	11/16/2023	11/17/2023
September 15, 2023	$0.20	08/17/2023	08/18/2023
June 15, 2023	$0.20	05/18/2023	05/19/2023
March 15, 2023	$0.20	02/15/2023	02/16/2023
December 15, 2022	$0.19	11/17/2022	11/18/2022
September 15, 2022	$0.19	08/18/2022	08/19/2022
June 15, 2022	$0.19	05/19/2022	05/20/2022
March 15, 2022	$0.19	02/17/2022	02/18/2022
December 15, 2021	$0.17	11/18/2021	11/19/2021
September 15, 2021	$0.17	08/19/2021	08/20/2021
June 15, 2021	$0.17	05/19/2021	05/20/2021
March 15, 2021	$0.17	02/18/2021	02/19/2021
December 15, 2020	$0.15	11/19/2020	11/20/2020
September 30, 2020	$0.15	09/14/2020	09/15/2020

Dividends Summary

Royalty Pharma plc Class A Ordinary Shares has issued 20 dividend payments over the past 5 years
The most recent dividend was paid 89 days ago, on March 10, 2025
The first recorded dividend was paid on September 30, 2020
The highest dividend payout was $0.22 per share
The average dividend over this 5 year span is $0.19 per share
Royalty Pharma plc Class A Ordinary Shares has increased its dividend payments by 46.67% since 2020

Company News

Royalty Pharma Completes the Acquisition of Its External Manager

Royalty Pharma has successfully completed the acquisition of its external manager, RP Management, LLC. This transaction is expected to enhance long-term shareholder value through a simplified corporate structure, strengthened shareholder alignment, enhanced governance, significant cash savings, and increased economic return on investments.

Benzinga
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

Royalty Pharma announced that its shareholders overwhelmingly approved the acquisition of its external manager, which is expected to result in significant cost savings and enhanced corporate governance.

Benzinga
Royalty Pharma Declares Second Quarter 2025 Dividend

Royalty Pharma announced a dividend of $0.22 per Class A ordinary share for the second quarter of 2025, payable on June 10, 2025 to shareholders of record on May 16, 2025.

Benzinga
Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma

Biogen reported strong Q4 earnings, but warned of lower revenue in 2025 due to declining multiple sclerosis drug sales. The company also announced an R&D funding pact with Royalty Pharma.

Benzinga

Featured Companies: BIIB
Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

Royalty Pharma announced it will acquire its external manager, RP Management, LLC, to simplify its corporate structure and generate significant cost savings. The company also approved a $3 billion share repurchase program.

Benzinga

Dividend data last updated 06/07/2025 20:11:29 UTC